Bio-Rad Labs (BIO) Tops Q1 EPS by 14c; maintains guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
This stock offers one of the most favorable long-term risk/rewards in biotech: RBC
May 8, 2024 4:30 PM EDTRBC Capital analysts highlighted one stock they believe has a favorable risk/reward in a note Wednesday.
The bank continues to view Bio-Rad Labs (NYSE: BIO) as one of the most compelling long-term investment opportunities in its coverage universe, emphasizing a favorable risk/reward profile.
Despite a 25%... More
Bio-Rad Labs (BIO) PT Lowered to $414 at RBC Capital
May 8, 2024 6:22 AM EDTRBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $414.00 (from $420.00) while maintaining a Outperform rating.
The analyst comments "We continue to view BIO as one of the most favorable long-term risk/reward names under coverage; though... More
